Aptus Pharma Limited has been recognized with the prestigious "Fastest Growing Ethical Pharma Company" award by News 18 Group, marking a significant milestone in the company's journey of ethical growth and healthcare excellence.

Award Presentation Details

The recognition was formally presented during a ceremony presided over by Hon'ble Deputy Chief Minister of Gujarat, Shri Harsh Sanghavi. The award ceremony showcased the company's achievements in the pharmaceutical sector and its commitment to ethical business practices.

Company Representatives

The honor was accepted on behalf of Aptus Pharma Limited by two key executives who represented the company at the formal ceremony. Mr. Kapil Chandarana, serving as Chief Financial Officer, and Mr. Mahipal Zala, Deputy Regional Sales Manager, received the award and trophy during the event.

Business Operations

Aptus Pharma Limited operates through multiple specialized divisions, each focusing on distinct market segments:

• Aptus Pharma (Pioneer Division): The company's flagship division
• APTUS CD CARE (Cardiac Diabetic Division): Specialized healthcare solutions
• APTUS WellCare (Health And Personal Care Division): Consumer health products
• APTUS Global (Export Division): International market operations

Recognition Significance

This recognition reflects the company's sustained growth and continued commitment to ethical business practices in the pharmaceutical industry. The award acknowledges Aptus Pharma's dedication to maintaining high standards while achieving significant growth in the competitive healthcare sector.

The company has formally notified BSE Ltd about this achievement through official communication, emphasizing the importance of this recognition for stakeholders and the broader pharmaceutical community.

Aptus Pharma Limited has released a comprehensive investor presentation to investors and analysts in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The presentation, disseminated on February 7, 2026, provides an overview of the company's business operations and financial performance based on publicly available information.

Company Overview and Business Model

Established in 2011, Aptus Pharma has positioned itself as a pharmaceutical sales company contributing to healthcare through quality products and customer satisfaction. The company operates across multiple therapeutic segments with both domestic and international presence through a dedicated export division.

The company follows a structured business process encompassing demand estimation, contract manufacturer selection, purchase order issuance, manufacturing, quality checks, and warehousing with marketing and distribution.

Growth Trajectory and Key Milestones

Aptus Pharma's expansion demonstrates consistent growth since incorporation. The company began operations in 2011 with 11 products and has systematically expanded its portfolio and geographic presence.

During 2021-25, the company strengthened its market presence by appointing a Vice President for Domestic Sales & Marketing, launching three domestic divisions, and entering the OTC and wellness segment. The operational headquarters shift from Rajkot to Ahmedabad supported national expansion plans, complemented by a centralized hi-tech depot and robust sales and distribution network.

Leadership and Management Structure

The company's leadership team brings extensive pharmaceutical industry experience. Tejash Maheshchandra Hathi, Managing Director since January 17, 2024, holds an MBA in Marketing and Management Accounting and brings over two decades of pharmaceutical industry experience. Ghanshyam Vinubhai Pansuriya was appointed Chief Executive Officer effective January 1, 2025, contributing over 15 years of pharmaceutical industry expertise.

The management team includes Non-Executive Directors Chetan Shantilal Lalseta, a consultant dermatologist with over 20 years of experience, and Riddhish Natwarlal Tanna, a homeopathic practitioner with healthcare management qualifications. Nirav J. Pandya serves as Vice President overseeing Pan-India operations with 27 years of pharmaceutical industry experience.

Strategic Vision and Future Plans

Aptus Pharma has outlined Vision 2026-30 focusing on horizontal and vertical expansion to establish strong Pan-India presence. The strategic plan includes launching 450+ products and expanding operational footprint across the country. The company operates through a robust contract manufacturing ecosystem, working with multiple manufacturing partners based on long-standing relationships built on consistent performance and quality standards.

Regulatory Compliance and Market Presence

The investor presentation complies with Regulation 46 of SEBI (LODR) Regulations, 2015, and will be available on the company's website under the Investor Relations section. The company maintains its commitment to quality through comprehensive due diligence of contract manufacturers, evaluating certifications, regulatory compliance, production capacity, and delivery reliability before approval.